Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Aspira Pathlab & Diagnostics's Revenue for the
three
months ended in Jun. 2026 was ₹61.7 Mil. Aspira Pathlab & Diagnostics's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹17.3 Mil.
Hence, Aspira Pathlab & Diagnostics's Receivables Turnover for the
three
months ended in Jun. 2026 was 3.56.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Aspira Pathlab & Diagnostics Receivables Turnover Related Terms
Aspira Pathlab & Diagnostics Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540788 vs TMO, DHR, NTRA: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Aspira Pathlab & Diagnostics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Pathlab & Diagnostics Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Pathlab & Diagnostics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Aspira Pathlab & Diagnostics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Pathlab & Diagnostics (BOM:540788) has a Receivables Turnover of 3.56 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Aspira Pathlab & Diagnostics and its competitors. According to the industry distribution chart, Aspira Pathlab & Diagnostics ranks #34 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 16.8%.
Is Aspira Pathlab & Diagnostics' Receivables Turnover too high?
Aspira Pathlab & Diagnostics' current Receivables Turnover is 3.56. The Medical Diagnostics & Research industry median Receivables Turnover is 5.40. Aspira Pathlab & Diagnostics' value of 3.56 is 34% below this industry median. Based on the distribution chart, Aspira Pathlab & Diagnostics ranks #34 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Aspira Pathlab & Diagnostics has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Pathlab & Diagnostics' Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Aspira Pathlab & Diagnostics ranks #34 out of 202 companies for Receivables Turnover. This places Aspira Pathlab & Diagnostics in the top 17% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.40. Aspira Pathlab & Diagnostics' value of 3.56 is 34% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.40, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspira Pathlab & Diagnostics's current Receivables Turnover of 3.56 is 34% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Aspira Pathlab & Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspira Pathlab & Diagnostics's current Receivables Turnover is 3.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Pathlab & Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics (BOM:540788) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹74.44, compared to a current price of ₹94.56 — trading 27% above its estimated fair value. The current Receivables Turnover is 3.56 and 34% below the Medical Diagnostics & Research industry median of 5.40. Aspira Pathlab & Diagnostics' overall GF Score™ is 53/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Aspira Pathlab & Diagnostics (BOM:540788), the current Receivables Turnover is 3.56 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspira Pathlab & Diagnostics (BOM:540788) Overvalued in 2026?
Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics stock appears to be overvalued.
The current stock price of ₹94.56 is trading 27% above its estimated GF Value™ of ₹74.44.
GuruFocus considers Aspira Pathlab & Diagnostics to be Modestly Overvalued.
Key valuation signals for BOM:540788:
Receivables Turnover: 3.56
GF Value™: ₹74.44 vs. price of ₹94.56 (27% above fair value)
Industry Position: 34% below the Medical Diagnostics & Research median (#34 of 202)
No single metric tells the full story. See the BOM:540788 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspira Pathlab & Diagnostics Ltd is mainly engaged in pathology and related healthcare services. It operates laboratories that conduct a wide range of pathological investigations across branches such as biochemistry, hematology, histopathology, microbiology, immunochemistry, immunology, virology, cytology, and other pathological and radiological tests. The services offered include pathology tests, sonography, X-rays, and radiology. The company also provides various health packages like gynecology profiles, anemia profiles, monsoon profiles, coagulation tests, cancer screening packages, newborn screening and IEM panels, orthopedic profiles, allergy panels, and cardiac profiles. These comprehensive diagnostic services assist in disease diagnosis.
53GF Score
Get the complete analysis for BOM:540788
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540788 has been successfully added to your 
